Ani Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 06, 2021 at 08:31 am EDT
Share
ANI Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 48.625 million compared to USD 48.470 million a year ago. Operating loss was USD 15.553 million compared to USD 11.307 million a year ago. Net loss was USD 14.106 million compared to USD 12.336 million a year ago. Basic loss per share from continuing operations was USD 1.17 compared to USD 1.03 a year ago. For the half year, sales was USD 103.146 million compared to USD 98.244 million a year ago. Operating loss was USD 12.508 million compared to USD 19.149 million a year ago. Net loss was USD 14.020 million compared to USD 19.347 million a year ago. Basic loss per share from continuing operations was USD 1.16 compared to USD 1.62 a year ago.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
